prominent ubiquilin 2-related pathology in the hippo campus of all patients with ALS-dementia, but not in ALS patients without demen tia, sug gesting that ubiquilin 2 is involved in ALS-related dementia. Interestingly, in non-UBQLN2-linked ALSdementia cases, the ubiquilin 2-positive inclusions were mostly negative for TDP-43. These new findings, therefore, add a new molecular piece to the ALS-FTLD puzzle, and further support the notion that these two disorders overlap in their underlying pathology. However, the relative frequencies of such protein abnormalities in these disorders remain to be determined.
Ubiquilin 2 is a member of the ubiquitinlike protein family (ubiquilins), which regulates the ubiquitin-proteasome system (UPS) of protein degradation by delivering ubiquinated proteins to the proteasome. To assess the functional consequences of UBQLN2 mutations, the investigators used a UPS reporter substrate, and showed a significantly slower degradation of this substrate in cells expressing mutant ubiquilin 2 than in cells expressing the wild-type protein.
In retrospect, ubiquilins were good candidate genes for ALS, as the UPS protein degradation pathway has been suspected to be linked to ALS for several years. 9, 10 Never theless, this study is the first to report mutations in a protein that is directly linked to the protein degradation pathway. Whether the disease is caused by a loss of ubiquilin 2 function or a gain of novel toxic properties is still to be determined, although several lines of evidence might suggest a gain of function. First, the identified mutations are clustered in the proline-rich region of the encoded protein, similar to the situation with TARDBP mutations, which are thought to cause gainof-function toxicity; moreover, all UBQLN2 mutations affect proline residues in one specific domain, suggesting that this domain could acquire novel toxic properties. Second, the UBQLN2 mutations act in a dominant X-linked manner. Last, in one male patient, mutated UBQLN2 did not lead to a disease phenotype, which is difficult to reconcile with a loss of function, given that males have only one copy of the X chromosome.
In summary, this study provides additional evidence for impairment of the pro tein degradation pathway in ALS-dementia. Whether ubiquilin 2 inclusions initiate neuro degeneration or are a consequence of intra cellular deregulation has yet to be es tablished. Animal models expressing UBQLN2 muta tions will be important in charac terizing the phenotypic consequences of these mutations. Altogether, this dis covery will, hopefully, lead to novel molecular targets for the de velopment of new treatment strategies for ALS.
Neurorestorative effects of glial cell linederived neurotrophic factor (GDNF) have been shown in gene therapy studies in animal models. Several different viral vectors, including adeno-associated viral vectors (AAV) or lentiviruses, have been used to administer GDNF in neurotoxin-induced rat and nonhuman primate models of Parkinson disease (PD). 1 Although GDNF was found to be promising in toxin-induced animal models of PD, the results from clinical trials have been mixed. Why, despite positive data from animal models, do clinical trials of GDNF in PD fail? Histological examination has shown that overexpression and aggregation of α-synuclein-a protein that is involved in dopamine transport and is naturally expressed in presynaptic terminals-is characteristic of patients with Parkinson disease (PD); however, aggregation of α-synuclein does not occur in many toxin-based models of PD. In a paper by Decressac et al., 2 published in Brain, researchers have investigated whether GDNF can protect against the neuro degenerative changes and cellular stress caused by the overexpression of α-synuclein. Clinical trials investigating the neuroprotective effect of GDNF in patients with PD have produced mixed results. In one trial, where a single patient was given monthly intracerebroventricular injections of GDNF, the individual showed no improvement in motor function and reported several adverse effects of the treatment. 3 However, in a small nonrandomized study in which GDNF was delivered directly into the putamen of five individuals with PD, the patients showed improvement in motor functions, as well as increased dopamine uptake (measured by PET), without any reported adverse effects. 4 In a larger randomized trial that included 34 PD patients, none of the participants showed improvement in motor function, but an increase in dopamine uptake was seen in the putamen of some patients after GDNF infusion. 5 In the paper by Decressac et al., 2 the authors questioned the relevance and predictability of toxin-based animal models for human disease. The researchers investigated whether GDNF had neuroprotective effects in an α-synuclein-overexpression model of PD, which mimics many features of human disease. They found that viral vectormediated delivery of GDNF into the substantia nigra and/or striatum did not prevent the loss of dopaminergic neurons and terminals in rats that overexpressed human α-synuclein. In addition, overexpression of GDNF did not reverse the behavioral changes seen in these animals. Measurement of striatal α-synuclein-positive aggregates showed that lentiviral expression of GDNF had no effect on α-synuclein aggregation. The authors conclude that GDNF does not have a neuroprotective effect in this α-synuclein-induced toxicity model of PD.
The study included an extensive series of well-executed experiments that involved administration of GDNF and α-synuclein using lentiviral and adeno-associated viral vectors. The paper documents the immunocytochemical and biochemical expression of GDNF, immunocytochemical measurements of midbrain dopamine circuitry in both the substantia nigra and striatum, and behavioral analysis of the transduced animals. Nonetheless, as with all 'negative' studies, a number of caveats should be considered.
After viral vector-mediated delivery of GDNF to the striatum or the substantia nigra, Decressac et al. showed larger areas of immunoreactivity in the brains of rats that received viruses containing GDNF than in those that received comparable titers of viruses containing green fluorescent protein (as a control vector). This finding suggests that GDNF was indeed secreted from the transfected neurons; however, a demonstration that the virally expressed GDNF was secreted in an active form would have been useful to confirm that the lack of efficacy of GDNF was not a result of the limited availability of the protein. GDNF activity cannot be ascertained by analyzing data from immuno cytochemical studies or ELISAs. Evidence that the GDNF-expressing neurons can provide trophic support for midbrain dopaminergic neurons by paracrine or autocrine release of GDNF is needed to confirm the neurotrophic 'potency' of the expressed protein. Demonstration that viral delivery leads to production of bioactive GDNF, as indicated by neurite outgrowth in vitro 6 or fiber sprouting in vivo, 7 would confirm that GDNF provided neurotrophic activity to the region. In addition, immunocyto chemical or biochemical evidence of upregulation of downstream signaling molecules, such as phosphorylated extracellular signal-regulated kinase (pERK), would verify the bioactivity of GDNF.
GDNF exerts its neurotrophic activity through binding to GDNF family receptor α-1 (GFR-α-1) and subsequent activation of the receptor tyrosine kinase RET, or through an interaction with neural cell adhesion molecule. The inability of GDNF to exert neurotrophic activity in Decressac et al.'s PD model could be attributable to loss of receptor expression in the α-synucleinoverexpressing cells, although the authors did not examine the effects of α-synuclein overexpression on the expression of GDNF receptor molecules.
The relevance of this model of α-synuclein overexpression to human PD is also unclear. Postmortem analysis of brains from PD patients indicates that RET immuno reactivity in the substantia nigra is similar to that in the brains of patients without PD. 8 No changes in RET or GFR-α-1 mRNA expression have been observed in the putamen in patients with PD. 9 Characterization of the effects of viral-vectorbased α-synuclein over expression on GDNF receptors in the substantia nigra and striatum would be important in understanding the inability of GDNF to confer protection. Strong over expression of a transgenic protein may alter the expression of receptors or other cellular proteins by interfering with cellular proteostasis. Overexpression of α-synuclein is associated with endo plasmic reticulum stress and activation of the unfolded protein response. As viral-vector-mediated delivery was not targeted solely to dopa minergic neurons, the unfolded protein response may also occur in cells that are not normally affected in PD, and this may cause further degenerative changes. 10 The possibility also exists that transcrip tional competition occurred between the two vectors, at least when both the α-synuclein-containing and GDNFcontaining viruses were injected into the same site (that is, in the substantia nigra). If the viruses were injected into the brain on the basis of volume and not titers, the numbers of viral particles that contained α-synuclein would be an order of magnitude higher than the numbers that contained GDNF. In this scenario, as the two vectors use similar cellular promoters, the competition for transcriptional factors would be heavily weighted towards α-synuclein expression. This could result in α-synuclein outcompeting the production of GDNF, thereby decreasing the effective dose of the latter protein. The levels of GDNF in the animals that were injected with both vectors are unknown, as assessment of the levels of GDNF was done only in the animals that were injected with vectors expressing GDNF. Measurements of GDNF production and signaling in animals injected with both GDNF-expressing and α-synuclein-expressing vectors are needed.
Future studies should explore whether the effects of viral-vector-based overexpression of α-synuclein on proteostasis are comparable to the changes in proteostasis observed in the brains of patients with PD. These studies may provide insight into the advantages and limitations of the model for evaluating GDNF or other neurotrophic factors as potential therapeutics for PD. Although a number of issues remain unresolved, further clinical trials with neurotrophic factors in PD seem to be warranted. The caveats described above notwithstanding, the study by Decressac et al. presents some interesting findings that stress the importance of studying potential PD therapies in more than just toxin-induced models.
